Clinical trials
Phase 2 Cytomegalovirus Infections trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
36 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2006 | 2 |
| 2009 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 27 |
| Active, not recruiting | 4 |
| Recruiting | 2 |
| Terminated | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 9 |
| ModernaTX, Inc. | 3 |
| City of Hope Medical Center | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| Albert Park | 1 |
| Amivas Inc. | 1 |
| Amy C. Sherman, MD | 1 |
| Astellas Pharma Inc | 1 |
| Genentech, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cytomegalovirus Infections | 36 |
| HIV Infections | 7 |
| Acquired Immunodeficiency Syndrome | 6 |
| Retinitis | 5 |
| Cytomegalovirus Retinitis | 4 |
| AIDS-Related Opportunistic Infections | 3 |
| DNA Virus Infections | 3 |
| Hodgkin Disease | 3 |
| Lymphoma, Non-Hodgkin | 3 |
| Multiple Acyl Coenzyme A Dehydrogenase Deficiency | 3 |
Trials
Showing 1 to 25 of 36. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.